The thioredoxin domain-containing 5 (TXNDC5) gene is associated with susceptibility to rheumatoid arthritis (RA) and exhibits increased expression in the synovial tissues. TXNDC5 is also associated strongly with diabetes, a metabolic disease characterized by interrupted insulin signalling. This study investigated whether TXNDC5 contributes to RA via the insulin signalling pathway. In this study, RA synovial fibroblast-like cells (RASFs) transfected with an anti-TXNDC5 small interfering RNA (siRNA) were analysed with an insulin signaling pathway RT 2 profiler polymerase chain reaction (PCR)
Introduction
Thioredoxin domain-containing 5 (TXNDC5) belongs to a family of protein disulphide isomerases and has three thioredoxin domains and an endoplasmic reticulum retention sequence at its C-terminus, resulting primarily in expression in the endoplasmic reticulum [1, 2] . TXNDC5 is a key enzyme in the rate-limiting reaction involved in disulphide bond formation, isomerization and reduction, which is important for the anti-oxidative injury and anti-apoptosis responses induced by anoxia and promotes cell proliferation [1] [2] [3] . Abnormal TXNDC5 expression plays an important role in the pathological processes of certain diseases, such as cancers, diabetes, neurodegenerative illnesses, vitiligo and arthritis [3] [4] [5] [6] [7] .
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease characterized by joint damage, synovial hyperplasia and irregular angiogenesis. In our previous studies, we revealed an association between the TXNDC5-encoding gene and RA risk. Additionally, TXNDC5 expression was up-regulated in synovial tissues and blood from RA patients in response to hypoxia stimulation [7] [8] [9] . However, the pathogenic role of this enzyme is unclear.
Diabetes mellitus is a metabolic disease characterized by hyperglycaemia and is caused by defective insulin secretion or an insulin function disorder. As shown in many studies, inflammatory activity and certain medications impact glucose metabolism, insulin signalling and insulin resistance and consequently drive diabetes development in RA [9] [10] [11] [12] [13] [14] [15] . Epidemiological studies have also confirmed an association between RA and an increased risk of diabetes [11, 14, 16] . Li et al. [17] recently sequenced the exomes of 8554 individuals and analysed the effects of predicted loss-of-function variants on 20 chronic disease risk factor phenotypes. Elevated fasting glucose levels were observed in individuals with heterozygous TXNDC5 loss-of-function variation, which encodes a biomarker for type 1 diabetes progression. According to Holmgren et al. [18] , TXNDC5 not only catalyzes a reduction in insulin disulphides to decrease binding activity with its receptor, but also reduces insulin synthesis, increasing the risk of diabetes. These studies suggest that TXNDC5 is associated with genetic susceptibility to both RA and diabetes and is involved in the pathogenesis of these two diseases. Thus, we hypothesized that TXNDC5 may play an important role in RA progression by modulating insulin resistance or insulin signalling pathways, similar to its role in diabetes. The present study aimed to determine whether TXNDC5 contributes to RA pathogenesis by modulating insulin resistance or insulin signalling pathways and investigated how TXNDC5 regulates this signalling. The results may also be helpful for understanding the strong association between RA and diabetes at the molecular level.
Materials and methods

Synovial tissue sample collection
Human RA synovial tissues were collected from RA patients during knee joint replacement surgery (n 5 10, nine females aged 23-68 years, mean 5 49 years) for tissue culture. We collected additional synovial samples from six RA patients (four females, aged 52-62 years, mean 5 52 years) for Western blot analysis of insulin-like growth factor binding protein 1 (IGBP1) expression. All RA patients met the standards of the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria. We also collected six synovial tissues from osteoarthritis (OA) patients during knee joint replacement surgery (two females aged 50-62 years, mean 5 52 years) to be used as controls. Informed consent was obtained from all patients, and the study was approved by the Ethics Committee of Shandong Provincial Qianfoshan Hospital (Jinan, China).
Cell culture
Synovial tissue samples were minced and digested with 0Á4 g/l collagenase type II (Solarbio, Beijing, China) for 6 h in Dulbecco's modified Eagle's medium (DMEM; HyClone, Logan, UT, USA) at 378C, after which they were redigested with 0Á25% trypsin for 15 min. The tissue suspensions were filtered through a 70-lm cell strainer, and the cells were then centrifuged, resuspended and cultured in DMEM containing 10% fetal bovine serum (GIBCO, Carlsbad, CA, USA) at 378C in 5% CO 2 for several days. RA synovial fibroblast-like cells (RASFs) were passaged five times and used for all experiments in this study.
Transient small interfering RNA (siRNA) transfection
RASFs were plated in six-well plates (2 3 10 5 cells per well) and transfected with an anti-TXNDC5 small interfering RNA (siRNA) using HiPerFect transfection reagent (Qiagen, Valencia, CA, USA) at 20 nM, according to the manufacturer's instructions. The sequence of the siRNA targeting theTXNDC5 mRNA was 5 0 -GGCCCTAACTAGAAGTTCTA -3 0 . Following transfection and culture for 72 h, RASFs were used for cell proliferation, cell migration and cell apoptosis assays. The supernatants of the transfected RASFs were also collected and centrifuged at 1000 3 g for 10 min, and then stored at 2808C until the enzyme-linked immunosorbent assay (ELISA). Inhibition of TXNDC5 expression was confirmed by performing real-time PCR and Western blot analyses. Parallel experiments applying the Mm/Hs-mitogen-activated protein kinase 1 (MAPK1) siRNA (5 0 -AA TGCTGACTCCAAAGCTCTG-3 0 ) and Allstars siRNA, which were included in the kit, were performed as positive and negative controls, respectively. The Allstars siRNA does not inhibit gene expression in any human cells.
We applied the same protocol to transfect RASFs with an anti-IGF binding protein 1 (IGFBP1) siRNA (5 0 -AGAG CACGGAGATAACTGA-3 0 ). In addition, we also transfected RASFs with a mixture of 10 mM anti-TXNDC5 siRNA and 10 mM anti-IGFBP1 siRNA.
Real-time PCR
Real-time PCR was performed on a ViiA7 DX Instrument (Life Technologies, Carlsbad, CA, USA) using SYBR Green (SYBR Green Real-time PCR Master Mix; Toyobo, Osaka, Japan). The PCR reactions were performed in a total volume of 10 ll and contained 1 ll of cDNA, 5 ll of SYBR Green real-time PCR Master Mix (Toyobo), 1 ll of each primer and 2 ll of water. The reaction conditions were set according to primer annealing temperatures. 
ELISA
IGFBP1 levels in RASF culture supernatants were measured using IGFBP1 ELISA kits (Abcam; ab100539). One hundred microlitres of cell culture supernatant were added into appropriate wells and incubated for 2Á5 h at room temperature. After four washes, 100 ll of biotinylated IGFBP1 antibody were added to each well, followed by incubation for 1 h at room temperature. After an additional four washes with wash solution, 100 ll of HRP-streptavidin solution were added to each well and incubated for 45 min at room temperature. Finally, 100 ll of TMB (3, 3 0 , 5, 5 0 -tetramethyl benzidine) one-step substrate reagent were added to each well and incubated for 30 min at room temperature. The reaction was stopped by adding 50 ll of stop solution to each well. The absorbance was read immediately at 450 nm using a spectrophotometer (Spectramax 190; Molecular Devices, Sunnyvale, CA, USA).
We applied a similar protocol to measure tumour necrosis factor (TNF)-a, interleukin (IL)-1a, IL-1b and IL-6 levels using ELISAs. RASFs were transfected with the Allstars siRNA, anti-TXNDC5 siRNA, anti-IGFBP1 siRNA or a mixture of anti-IGFBP1 siRNA and anti-TXNDC5 siRNA for 72 h. The culture medium was collected and centrifuged at 3000 g for 10 min at 48C. Levels of TNF-a, IL-1a, IL-1b and IL-6 were measured using ELISA kits provided by R&D Systems (Minneapolis, MN, USA). The experiment was conducted according to the manufacturer's protocol. The absorbance at 405 nm was measured using a plate reader.
Cell proliferation assay
Cell proliferation levels were evaluated using the cell counting kit-8 (CCK-8) as a marker for cellularity after defined culture periods. RASFs (10 3 10 3 cells/well) were dispensed into 96-well round-bottomed microtitre plates in a total volume of 100 ll/well. RASFs were transfected with Allstars siRNA, anti-TXNDC5 siRNA, anti-IGFBP1 siRNA or a mixture of anti-IGFBP1 siRNA and anti-TXNDC5 siRNA.
The incubation was performed for 24, 48 or 72 h at 378C. Ten microlitres of CCK-8 solution (Dojindo, Kumamoto, Japan) in 100 ll of complete DMEM medium were added to each well and incubated for 2 h. The plates were read on a spectrophotometer at an absorbance of 450 nm.
Transwell migration assay
Twenty-four-well transwell polycarbonate filters with an 8Á0-lm pore size (Corning, NY, USA) were used to detect RASF migration ability. RASFs were transfected with Allstars siRNA, anti-TXNDC5 siRNA, anti-IGFBP1 siRNA or a mixture of anti-IGFBP1 siRNA and anti-TXNDC5 siRNA. A total of 5 3 10 4 RASFs/200 ll of serum-free DMEM medium was seeded into the upper chambers for 48 h following transfection, and 600 ll of DMEM medium containing 10% fetal bovine serum (GIBCO-BRL) was added to the lower chamber. After incubation at 378C in 5% CO 2 for 24 h, the cells that migrated to the lower side of the filter were immersed in methanol for 15 min at room temperature, then stained with 0Á25% crystal violet for 10 min at room temperature. The cells that migrated to the underside of the filter were photographed (magnification 34) and counted (magnification 310) using an inverted microscope.
Cell apoptosis analysis
Apoptosis was detected using a fluorescein isothiocyanate (FITC)-annexin V and propidium iodide (PI) kit (Biolegend, San Diego, CA, USA), according to the manufacturer's instructions. RASFs were transfected with siRNAs as described above and plated on six-well culture plates (Costar, Cambridge, MA, USA) at a density of 50 3 10 
Statistical analysis
In this study, paired and/or unpaired Student's t-tests were used to evaluate the statistical significance of differences between two groups. One-way analysis of variance (ANOVA) was used to compare differences among multiple groups in the experiments. Statistical differences were considered significant at P < 0Á05. The Kolmogorov-Smirnov (K-S) test was performed to test whether the data followed a normal distribution.
Results
Detection of gene expression in anti-TXNDC5 siRNAtransfected RASFs
RASFs were transfected with the anti-TXNDC5 siRNA. Real-time PCR and Western blotting were conducted to determine the knock-down efficiency of the anti-TXNDC5 siRNA in RASFs (n 5 10) 72 h after transfection. Real-time PCR detected significantly decreased TXNDC5 mRNA expression in each anti-TXNDC5 siRNA-transfected synovial sample compared with that in RASFs transfected with the Allstars siRNA (P < 0Á0001). The Western blot analysis also detected significantly decreased expression of the TXNDC5 protein in each anti-TXNDC5 siRNA-transfected synovial sample compared with that in RASFs transfected with the Allstars siRNA (P < 0Á0001). These results are presented in Supporting information, Fig. S1 . Equal concentrations of total RNA from each sample were pooled and analysed by PCR array. An insulin signaling pathway RT 2 profiler PCR array and an insulin resistance RT 2 profiler PCR array were used to identify any significant changes in gene expression between anti-TXNDC5 siRNA-transfected RASFs and negative control siRNA-transfected RASFs. The insulin signaling pathway RT 2 profiler PCR array detected a significant increase (5Á56-fold) in IGFBP1 mRNA expression in RASFs transfected with the anti-TXNDC5 siRNA (Fig. 1a) . The insulin resistance RT 2 profiler PCR array detected a significant increase (4Á06-fold) in PCK1 expression and a decrease in insulin-like growth factor 1 (IGF-1) expression (3Á85-fold), SLC2A4 expression (7Á07-fold) and interleukin 1 receptor type 1 (IL1R1) expression (3Á58-fold) in anti-TXNDC5 siRNA-transfected RASFs (Fig. 1b) . The PCR array results are depicted in one map (Fig. 1c) . IGF1, IGFBP1, IL1R1, PCK1 and SLC2A4 mRNA levels were analysed in RASF obtained from every patient (n 5 10) by performing real-time PCR analyses. Mean IGFBP1 mRNA levels were elevated significantly (twofold; P 5 0Á018) in anti-TXNDC5 siRNA-transfected RASFs (Fig. 2a) , but no significant changes in the expression of IGF1, IL1R1, PCK1 and SLC2A4 were detected in anti-TXNDC5 siRNA-transfected RASFs compared with that in RASFs transfected with the Allstars siRNA (P 5 0Á218, P 5 0Á377, P 5 0Á701 and P 5 0Á367, respectively) ( Fig. 2b-e) . We also examined the mRNA levels of IGFBP3, the primary IGF-1 binding protein. IGFBP3 levels were increased slightly in anti-TXNDC5 siRNA-transfected RASFs, but the difference was not significant (P 5 0Á306) (Fig. 2f) . A Western blot analysis was performed next to examine the expression of the IGFBP1 protein in TXNDC5 knock-down RASFs. Elevated IGFBP1 expression (threefold) was detected in anti-TXNDC5 siRNA-transfected RASFs compared with that in Allstars siRNA-transfected RASFs (P < 0Á0001) (Fig. 3) .
ELISA was performed to detect concentrations of the IGFBP1 protein in culture supernatants of TXNDC5 knock-down RASFs (n 5 10). Elevated levels (1Á75-fold) of IGFBP1 (350 pg/ml) were detected in the medium obtained from anti-TXNDC5 siRNA-transfected RASFs compared to those in Allstars siRNA-transfected RASFs (200 pg/ml) (P 5 0Á001). The results are presented in Fig. 4 . Fig. S1 because the K-S test showed that the data were distributed normally (P > 0Á05).
Inhibition of TXNDC5 on IGFBP1 in RA
V C 2017 British Society for Immunology, Clinical and Experimental Immunology, 192: 82-94 We used paired t-tests to compare results from cells transfected with the Allstars negative control siRNA and anti-TXNDC5 siRNA shown in Figs 2-4 and Supporting information,
Detection of RASF proliferation, migration and apoptosis
Cell proliferation, cell migration and apoptosis assays were performed to determine the effects of anti-TXNDC5 siRNA on cultured RASFs (n 5 10). The expression of the TXNDC5 mRNA was decreased significantly in anti-TXNDC5 siRNA-transfected RASFs compared with that in cells transfected with the negative control siRNA, as shown in Supporting information, Fig. S1 . RASFs were also transfected with an anti-IGFBP1 siRNA. We used paired t-tests to compare results from cells transfected with the Allstars negative control siRNA and anti-IGFBP1 siRNA because the K-S test showed that the data were distributed normally (P > 0Á05). The efficacy of IGFBP1 silencing after anti-IGFBP1 siRNA transfection is shown in Supporting information, Fig. S2 . IGFBP1 mRNA and protein expression were decreased significantly in anti-IGFBP1 siRNA-transfected RASFs compared with that in cells transfected with the negative control siRNA (P 5 0Á025 and P 5 0Á003, respectively).
RASF proliferation was measured using the CCK-8 assay. Seventy-two h after transfection with the antiTXNDC5siRNA, RASF proliferation was decreased significantly upon down-regulation of TXNDC5 expression compared with that in Allstars siRNA-transfected RASFs (P 5 0Á012). When RASFs were transfected with the anti-IGFBP1 siRNA, cell proliferation was elevated significantly compared with that in the group transfected with the Allstars siRNA (P 5 0Á036). When RASFs were transfected with a mixture of the anti-IGFBP1 siRNA and anti-TXNDC5 siRNA, RASF proliferation was not changed considerably compared with that in the group transfected with the Allstars siRNA (P 5 0Á776). The results are shown in Fig. 5 . These observations indicated that transfection with the anti-TXNDC5 siRNA suppressed RASF proliferation considerably, and transfection with the anti-IGFBP1 siRNA or a mixture of the anti-IGFBP1 and anti-TXNDC5 siRNAs elevated the proliferation ability significantly compared to the control.
The cell migration ability of RASFs was measured using a two-compartment transwell system. Cell migration was reduced significantly in anti-TXNDC5 siRNAtransfected RASFs compared with that in Allstars siRNA-transfected RASFs (P < 0Á0001). When RASFs were transfected with the anti-IGFBP1 siRNA, migration was changed significantly compared with that in the group transfected with the Allstars siRNA (P 5 0Á038). When RASFs were transfected with the mixture of the anti-IGFBP1 siRNA and anti-TXNDC5 siRNA, migration ability was not changed significantly compared with that in the group transfected with the Allstars siRNA (P 5 0Á766). The results are shown in Fig. 6 . These observations indicated that transfection with the anti-TXNDC5 siRNA retard RASF migration considerably and transfection with the anti-IGFBP1 siRNA elevate the migration ability significantly, although the transfection with a mixture of the anti-IGFBP1 and anti-TXNDC5 siRNAs did not change the RASF migration level significantly compared to the control.
RASF apoptosis was measured using flow cytometry. The apoptosis rate was increased to a certain extent in anti-TXNDC5 siRNA-transfected RASFs compared with that in Allstars siRNA-transfected RASFs (P 5 0Á032). When RASFs were transfected with the anti-IGFBP1 siRNA, the apoptosis rate did not show a significant change compared with that in the group transfected with the Allstars siRNA (P 5 0Á092). When RASFs were transfected with the anti-IGFBP1 and anti-TXNDC5 siRNA mixture, the apoptosis rate did not show a significant change compared with that in the group transfected with the Allstars siRNA (P 5 0Á855). The results are shown in Fig. 7 . These observations indicated that transfection with the anti-TXNDC5 siRNA elevated RASF apoptosis significantly, but transfection with the anti-IGFBP1 siRNA or the mixture of the anti-IGFBP1 did not change RASF apoptosis compared to the control.
Detection of IGFBP1 expression in RA synovial tissues
We examined IGFBP1 expression in RA synovial membranes (n 5 6) and OA synovial membranes (n 5 6). We used the unpaired t-test to compare results from RA and OA samples because the K-S test showed that the data were distributed normally (P > 0Á05). Real-time PCR detected significantly decreased IGFBP1 expression in RA synovial tissues compared with that in OA synovial tissues (P 5 0Á011) (Fig. 8a) . A Western blot analysis was also used to detect levels of the IGFBP1 protein in synovial tissues. IGFBP1 expression was decreased significantly by an average of twofold in RA synovial tissues compared with that in OA samples (P 5 0Á014) (Fig. 8b,c) .
Detection of IL-6 levels in RASF culture supernatants
An ELISA was performed to determine the IL-6 levels in culture supernatants of TXNDC5 knock-down RASFs (n 5 10). The IL-6 level was decreased significantly (2Á96 ng/ml) in culture medium from anti-TXNDC5 siRNAtransfected RASFs compared to that in medium from Allstars siRNA-transfected RASFs (4Á22 ng/ml, P 5 0Á048). In contrast, the IL-6 level was increased significantly in culture medium from RASFs transfected with the anti-IGFBP1 siRNA (8Á60 ng/ml) and in culture medium from RASFs transfected with a mixture of the anti-IGFBP1 siRNA and anti-TXNDC5 siRNA (9Á74 ng/ml) compared to that in medium from cells transfected with the Allstars siRNA (P 5 0Á002 and P 5 0Á001, respectively). The results are presented in Fig. 9 . These observations indicated that transfection with the anti-TXNDC5 siRNA suppressed IL-6 production in RASFs significantly, and transfection with the anti-IGFBP1 siRNA or a mixture of the anti-IGFBP1 and anti-TXNDC5 siRNAs elevated IL-6 production considerably compared to the control. Although we detected significantly decreased levels of TNF-a, IL-1a and IL-b in RASFs transfected with anti-TXNDC5 siRNA in a previous study, the current study did not detect significant changes in TNF-a, IL-1a and IL-1b levels in RASFs transfected with either the anti-IGFBP1 siRNA or the mixture of the anti-IGFBP1 siRNA and anti-TXNDC5 siRNA compared with those in the Allstars siRNA-transfected control group. These results are not shown.
We used ANOVAs with corrections for multiple comparisons to compare the four groups of data shown in Figs 5-7 and 9 because the K-S test showed that the data were distributed normally (P > 0Á05). We compared the means of each group to the mean of the Allstars siRNA-transfected group using Dunnett's multiple comparison test.
Discussion
In the present study, a PCR array analysis detected increased expression of IGFBP1 in RASFs in which TXNDC5 expression was inhibited using an siRNA. This result was verified at both the transcriptional and translational levels by performing real-time PCR and Western blotting, respectively. An ELISA also detected significantly elevated levels of IGFBP1 in the supernatants of transfected RASFs. In addition, significantly decreased IGFBP1 expression was detected in RA synovial tissues. Previously, we detected significantly increased TXNDC5 expression in the synovial membranes, synovial fluids and blood of RA patients [7] . These results suggest that increased TXNDC5 expression down-regulates IGFBP1 expression in RA synovial tissues. The current study did not detect significantly altered expression of genes involved in the insulin resistance pathway when TXNDC5 expression was suppressed in the siRNA-transfected RASFs. Thus, TXNDC5 does not appear to be associated with the insulin resistance pathway in RA, although some studies have reported the importance of this signalling pathway in its pathogenesis [19, 20] .
We performed immunohistochemistry previously to localize the expression of TXNDC5 in RA synovial membranes. The immunohistochemistry analysis revealed extensive TXNDC5 expression in the fibroblast-like cells of the synovial membranes from RA patients [8] . These results indicate that TXNDC5 is expressed mainly in RASFs, but not in other types of synovial cells such as B cell clusters and infiltrating T cells. In the present study, we tried to examine the immunolocalization of TXNDC5 and IGFBP1 in RA synovial tissues. Consistent with our previous results, immunohistochemistry revealed the localization and substantial expression of TXNDC5 in RA synovial fibroblast-like cells [8] . However, significant expression of IGFBP1 was not observed in RA synovial tissues. The real-time PCR and Western blot analyses showed that the expression of IGFBP1 was low in RA synovial tissues, and the ELISA results showed that the IGFBP1 protein was secreted in the supernatant of cultured RASFs. Based on these results, the unsuccessful immunolocalization of IGFBP1 in RA synovial membranes is due to inhibition of IGFBP1 expression in these tissues by the increased TXNDC5 levels.
IGF-1 is a hormone with a similar molecular structure to insulin, which exerts growth-promoting effects on almost every cell type in the body. Following binding with IGF receptors, IGF exhibits tyrosine kinase activity and activates signalling pathways such as phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) and RAS/MAPK, thus affecting cell proliferation, differentiation, survival and apoptosis [21] . IGF activity is regulated finely by a family of six high-affinity IGFBPs. IGFBPs usually inhibit IGF actions but prolong the IGF half-life [22] . Therefore, the IGF/IGFBP molar ratio is considered a better indicator of IGF bioavailability than IGF itself [22, 23] . IGFBP3 is the most abundant of the IGFBPs and forms a complex with IGF-1 to serve as a reservoir of IGF-1 in the circulation. IGFBP3 levels are significantly higher in patients with RA and notably elevated in patients with active RA. IGFBP3 sensitizes RASFs to TNF-a-induced apoptosis in vitro and increases apoptosis significantly in an in-vivo model of Matrigel implants engrafted into immunodeficient mice [24] . However, the present study did not detect significant alterations in IGFBP3 expression in RASFs following transfection of the anti-TXNDC5 siRNA. This result suggests that TXNDC5 modulates IGFBP1 rather than IGFBP3 expression in RASFs to affect IGF activity. IGFBP1 also binds IGF-1 with high affinity, prolongs the half-life of IGFs and mediates the interactions between IGF and its cell surface receptors to modulate the downstream signalling pathway [25, 26] . The current study detected little change in IGF-1mRNA levels in RASFs transfected with the anti-TXNDC5 siRNA. Lee et al. [27] and Toussirot et al. [28] also detected no changes in IGF-1 levels in RA using ELISA. Thus, we consider that the increased IGFBP1 expression observed in RASFs in which TXNDC5 expression was suppressed results in a decreased IGF-1/IGFBP1 ratio. Additionally, we detected significantly decreased expression of IGFBP1 in RA synovial tissues. The above results suggest that TXNDC5 over-expression leads to increased IGF activity by inhibiting IGFBP1 expression in RA synovium in vivo.
RASFs are the primary constituents of the synovial lining of the RA joint. In the current study, we observed decreased RASF proliferation and migration, as well as increased RASF apoptosis following anti-TXNDC5 siRNA transfection, whereas IGFBP1 expression was increased. When RASFs were transfected with the anti-IGFBP1 siRNA or a mixture of the anti-IGFBP1 siRNA and TXNDC5 siRNA, the proliferation and migration of RASFs were restored to normal levels or to levels even higher than RASFs transfected with the Allstars siRNA, although the apoptosis rate did not change compared to RASFs transfected with the Allstars siRNA. These results suggest that increased TXNDC5 expression in RA synovial tissues contributes to abnormal RASF proliferation and migration by reducing IGFBP1 levels and subsequently increasing IGF activity in vivo. IGF-1 is produced primarily by macrophages in the RA synovium. TNF-a, a proinflammatory cytokine, has been shown to induce aberrant IGF-1 production in RASFs. Inhibition of the insulin-like growth factor system may be a potential therapy for RA [26, 29] . IGF exerts potent prosurvival and anti-apoptotic activities [30, 31] . IGF-1 plays an anti-apoptotic role by activating PI3K/Aktregulated glycometabolism [32] . The IGF family increases tumour cell proliferation and transformation and inhibits cell apoptosis [33] , consistent with our observations in the present study.
In the present study, a significant decrease in IL-6 levels was detected in the culture medium of RASFs following transfection with the anti-TXNDC5 siRNA, and IL-6 levels were elevated significantly in the supernatants of RASFs transfected with the anti-IGFBP1 siRNA or a mixture of the anti-IGFBP1 siRNA and anti-TXNDC5 siRNA compared to those in the control group. This observation reveals that TXNDC5 can up-regulate IL-6 levels by suppressing IGFBP1 expression. IL-6 is a proinflammatory cytokine involved in the pathogenesis of various autoimmune and chronic inflammatory diseases, and plays a key role in RA. The IL-6 inhibitor, tocilizumab, a humanized anti-IL-6 receptor monoclonal antibody, shows outstanding efficacy in RA [34, 35] . We have detected significant increases previously in IL-1a, IL-1b, IL-17 and TNF-a production in TXNDC5-over-expressing mice and decreases in the expression of these cytokines in RASFs transfected with the anti-TXNDC5 siRNA [9] . Thus, we suggest that TXNDC5 decreases IL-6 production rather than the production of other cytokines by regulating IGFBP1 expression. IGF-1 receptor signalling was shown recently to contribute to IL-6 production in RA [36] , which supports our findings.
Increasing evidence suggests an important role for the IGF-IGFBP axis in the maintenance of normal glucose and lipid metabolism in diabetes. Low circulating levels of IGFBP1 are associated with insulin resistance and predict the development of type 2 diabetes [37] [38] [39] , which corresponds with our observations of low IGFBP1 expression in RA synovial tissues. Additionally, some clinical studies have reported an association between low IGF-1 levels or a genetic polymorphism and an increased risk of glucose intolerance or diabetes [40, 41] . Schneider et al. suggested that both low and high IGF-1 levels increase the risk of diabetes [42] . Recent studies have revealed the importance of TXNDC5 in diabetes [17, 18] . The current study provides evidence that high expression of TXNDC5 suppresses IGFBP1 expression. Based on our observations and those of others, we suggest that abnormal TXNDC5 expression and the subsequent interruption of IGFBP1 expression is involved in the pathogenesis of both RA and diabetes, which explains the strong association between these two diseases.
In recent years, several studies have shown that many of the inflammatory molecules that play a pathogenic role in RA are also involved in type 2 diabetes [43] [44] [45] [46] . Both preclinical and clinical observations have reported the efficacy of IL-1b antagonism therapy in both type 2 diabetes and RA [47] [48] [49] . We observed a significant increase in IL-1b, IL-1a, IL-17 and TNF-a production in TXNDC5-overexpressing mice [9] , which was decreased in RASFs following transfection with the anti-TXNDC5 siRNA. Thus, the up-regulation of the expression of inflammatory molecules, such as IL-1a, IL-1b, IL-17 and TNF-a, by TXNDC5 may also explain the strong association between RA and diabetes.
In summary, the present study found that inhibiting TXNDC5 expression in RASFs resulted in increased IGFBP1 expression but not IGFBP3 and IGF-1 expression. IGFBP1 is expressed at low levels in RA synovial tissues. Thus, increased expression of TXNDC5 in the RA synovium may down-regulate IGFBP1 expression and consequently increase IGF activity, which may upregulate cell proliferation, migration and IL-6 production. The effects of TXNDC5 down-regulation on IGFBP1 expression also help to explain the high occurrence of diabetes in RA patients and the molecular link between these two diseases, because reduced IGFBP1 expression and abnormal TXNDC5 activity have been reported in diabetes. 
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